CIK 0001604821
- Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 010894487
- Phone
- +1 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −3,320 | $107.59 | $357K | 219,456 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Exercise or conversion 10b5-1 | +30,000 | $19.68 | $590K | 234,495 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −5,997 | $101.55 | $609K | 228,498 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −9,398 | $102.91 | $967K | 219,100 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −4,255 | $104.03 | $443K | 214,845 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −10,350 | $108.10 | $1.1M | 204,495 |
| 2024-05-10 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 12,500 | ||
| 2024-05-10 | Sheena Jonathan Director | Sale 10b5-1 | −349 | $103.06 | $36K | 321,412 |
| 2024-05-10 | Sheena Jonathan Director | Sale 10b5-1 | −990 | $104.60 | $104K | 320,422 |
| 2024-05-10 | Sheena Jonathan Director | Sale 10b5-1 | −660 | $105.51 | $70K | 319,762 |
| 2024-05-10 | Sheena Jonathan Director | Sale 10b5-1 | −611 | $106.32 | $65K | 319,151 |
| 2024-05-10 | Sheena Jonathan Director | Sale 10b5-1 | −90 | $107.48 | $10K | 319,061 |
| 2024-05-08 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Exercise or conversion | +215,000 | $5.40 | $1.2M | 1,290,648 |
| 2024-05-08 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Exercise or conversion · Stock Option (right to buy) | −215,000 | 398,496 | ||
| 2024-05-01 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −400 | $92.60 | $37K | 69,008 |
| 2024-05-01 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −866 | $93.88 | $81K | 68,142 |
| 2024-05-01 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −400 | $94.70 | $38K | 67,742 |
| 2024-05-01 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −200 | $95.64 | $19K | 67,542 |
| 2024-04-29 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,196 | $93.14 | $111K | 115,833 |
| 2024-04-29 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −929 | $93.14 | $87K | 110,748 |
Page 72 of 85 · 1,682 trades